News

Loss from operations was $908,465, compared to $1.29m for the comparable period in 2009. For the nine months ended 30 September 2010 Catalyst posted a net loss of

According to China Biologic Products, the revenue growth was primarily attributable to price increases ranging from 6.2% to 55.8% across the company’s approved product categories, with the exception

Invented and developed by Neogenix, the antibody has shown anti-tumor effects for both pancreatic and colorectal tumors in both in-vitro and animal studies and may have both therapeutic

Pixantrone is a new aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Previously, the Pediatric Committee (the

The US District Court for the District of Delaware’s decision came in the case of Eli Lilly et al v. Teva Parenteral Medicines, et al. Eli Lilly senior

The company has collaborated with the University of California, San Francisco marking the first collaboration in the entrepreneurial network of research partnerships. Pfizer Worldwide Research & Development president

According to the company, increased demand from customers in the pharmaceutical, food and cosmetic industries were the primary contributors for revenue growth during the period. China Ruitai has

Strasbourg, France-based NovAliX Group is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry’s outsourcing needs from discovery to manufacturing. Heidelberg, Germany-based